Methods for Quantification of Tissue Features in Cancer Biology

Cancer is a disease that arises from the abnormal growth and division of cells in the body, and is driven by a variety of genetic and environmental factors. It is one of the leading causes of death worldwide, and despite significant progress in cancer treatment in recent years, there is still a need for better understanding of the biology of cancer. One important area of research in cancer biology is the study of tissue features in cancer cells, which can provide insights into the underlying mechanisms driving cancer progression and may help to identify new targets for therapy.

Histology is the study of tissues, and plays an important role in the study of cancer biology. One of the most common histological techniques used in cancer research is Hematoxylin and Eosin (H&E) staining. This technique helps in the visualization of the basic tissue architecture of a sample, such as the shape and size of cells, as well as the presence of any abnormalities. The technique works by staining the nuclei of cells with hematoxylin, a basic dye, and the cytoplasm and extracellular matrix with eosin, an acidic dye. This creates a contrast between different types of cells and tissues, allowing for the visualization and interpretation of the sample.

Another important histological technique is immunohistochemistry (IHC), which allows for the visualization of specific proteins in tissue samples. IHC works by using antibodies that are specific to a particular protein of interest, which are labeled with a fluorescent or chromogenic dye. The labeled antibodies bind to the protein of interest in the tissue sample, which can then be visualized under a microscope. IHC can be used to identify specific proteins that are overexpressed in cancer cells, such as Tumor Associated Antigens, which can help to diagnose

and classify tumors, and to identify potential targets for therapy.

Immunotherapy is a rapidly evolving area of cancer research, which involves using the body's own immune system to fight cancer. The immune system plays a critical role in identifying and destroying abnormal cells in the body, including cancer cells. However, cancer cells are often able to evade the immune system by producing proteins that suppress the immune response. Immunotherapy aims to overcome this suppression and to stimulate the immune system to recognize and attack cancer cells. There are several different types of immunotherapy, including

checkpoint inhibitors, cancer vaccines and adoptive cell therapies such as CAR-T cell and TCR-T cell therapy.

Machine learning (ML) and deep learning (DL) are two types of artificial intelligence that are increasingly being used in cancer research. ML involves training algorithms to identify patterns in large datasets, which can then be used to make predictions or identify new targets for therapy. DL is a subset of ML that involves training neural networks to perform complex tasks, such as image analysis. DL has been used to analyze histological images and to identify patterns that are difficult for human experts, such as pathologists, to detect. ML and DL can thus, improve the accuracy of cancer diagnosis and prognosis.

Histological Techniques

1. Hematoxylin and Eosin Staining:

Hematoxylin and eosin (H&E) staining is one of the most widely used stains in cancer pathology. It is a type of histological staining that uses a combination of two dyes, hematoxylin and eosin, to stain different structures in tissue samples. Hematoxylin stains the nucleus black, and helps in visualizing intranuclear components, while eosin stains the cytoplasm and connective fibers in various shades of red, orange and pink[1]. This differential staining allows pathologists to analyze cellular and tissue morphology. It is commonly used to identify cancer cells, determine tumor grade, assess tissue architecture, and detect other tissue features. The information obtained from H&E staining can provide important diagnostic and prognostic information.

H&E staining is commonly used to identify cancer cells in tissue samples. Cancer cells typically

have an abnormal morphology, with enlarged, non-centred nuclei, altered chromatin structure, and irregular cell boundaries. These features can be visualized using H&E staining, allowing pathologists to differentiate between normal and cancerous tissue[2].

H&E staining can also be used to determine the grade of a tumor, which is an important prognostic factor in cancer. Tumor grade is based on the degree of cellular differentiation and the presence of mitotic figures, which are visualized using H&E staining. Higher-grade tumors are associated with poorer outcomes and may require more aggressive treatment. H&E staining can also be used to assess the tissue architecture of tumors and surrounding stromal tissue. This can provide important information about the extent of tumor invasion and the presence of tumor-associated stromal cells[3].

In addition to its use in cancer diagnosis and grading, H&E staining can also be used to detect other tissue features, such as inflammation, necrosis, and fibrosis. These features can provide important information about the pathophysiology of the tumor.

2. Immunohistochemistry:

Immunohistochemistry (IHC) microscopy is a type of brightfield staining technique used in cancer pathology to detect specific proteins or antigens in tissue samples. This technique is based on the principle of using antibodies that bind specifically to the protein of interest, which are then visualized using a staining method. IHC microscopy is an important technique in cancer pathology that allows pathologists to detect specific proteins or antigens, identify tumors of unknown origin, assess the tumor microenvironment, and detect prognostic markers. The information obtained from this technique can be used to both identify the exact origin of the tumor and to determine the type of treatment to be used.

IHC microscopy is commonly used to detect specific proteins or antigens in cancer tissue samples. Antibodies that bind specifically to the protein of interest are labeled with a chromogen, which produces a visible color reaction in the tissue when the antibody binds to the protein. This allows pathologists to visualize the distribution and expression of the protein in the tissue sample.

IHC microscopy can also be used to identify tumors of unknown origin, which have metastasized and are hard to trace back to their primary origin. This is achieved by using antibodies that bind specifically to markers of different cell types. Panels of antibodies are often used, and the antibodies are determined by looking at the cells' general morphology, the patient's clinical history and other relevant tests.

IHC microscopy can also be used to assess the tumor microenvironment, including the presence

of immune cells and their activation status. This too has implications for the kind of cancer therapy which the patient should be given.

IHC microscopy can be used to detect prognostic markers in cancer tissue samples. These markers can provide important information about the likelihood of disease recurrence and the therapeutic response. It is used especially for the detection of estrogen and androgen receptors in breast or prostate tumors, and the levels of these receptors help in deciding how well the patient will respond to therapy[4].

Both H&E staining and IHC staining have their own advantages and disadvantages in cancer pathology. H&E staining is a simple method and provides a general overview of tissue morphology, such as the size, shape and surroundings of the tumor. It can be used to identify certain histological subtypes of cancer, but it is limited in its ability to detect specific molecular markers and cannot detect proteins with low levels of expression very reliably. IHC staining

allows for the detection of specific molecular markers and can be used to identify very specific cell types, such as cancer, immune and stromal cells. It can also detect protein expression levels, which help to identify how aggressive a tumor can be and what treatment should be done. However, it requires specialized reagents and equipment and is not an easily accessible method. For accurate diagnosis of a tumor, it is recommended that both H and E staining and IHC be done on the same tissue sample[5].

Multiplex IHC is an improved version of conventional IHC, in which there can be simultaneous detection of multiple markers on a single tissue section. It involves labeling different antibodies with their own fluorophore or chromogen, which then bind to their specific antigens on the surface of cancer cells and can be visualized at the same time.

mIHC has several advantages over single-plex IHC. Since we can detect multiple proteins at the same time, and in the same sample, it is useful when studying complex processes which involve many signaling pathways. This process also can reduce the time and resources needed for multiple staining procedures, and is a more efficient method. mIHC is useful when the sample that is available is very small. It also allows for a better understanding of the spatial distribution of immune cells and markers, as well as the interactions between immune, cancer and stromal cells. Thus, mIHC is an approach which provides a more comprehensive view of the entire complex immune microenvironment[6].

Immune Cell Therapy

Adoptive cell therapy is a type of immunotherapy where immune cells that have been genetically modified to target cancer cells are transferred into the patient in amounts that are greater than

would have been observed in an endogenous response. In this type of therapy, T cells are isolated from the patient, primed, amplified in vitro, and then transferred back to the patient. Two types of adoptive cell therapy that have shown promising results in clinical trials are chimeric antigen receptor (CAR)-T cell therapy and T cell receptor (TCR)-T cell therapy.

CAR-T cell therapy involves the engineering of T cells to express a chimeric antigen receptor (CAR) on their surface. The CAR is composed of an extracellular domain that recognizes a specific antigen on the surface of cancer cells and an intracellular domain that activates the T cell to kill the cancer cell. Once the CAR-T cells are infused into the patient, they migrate to the tumor site and target cancer cells expressing the antigen recognized by the CAR. However, they can only target cell surface antigens, and hence are not very effective in targeting solid tumors, due to the scarcity of antigens available on their surface[7].

TCR-T cell therapy involves the genetic modification of T cells to express a T cell receptor (TCR) that recognizes a specific antigen presented by the major histocompatibility complex

(MHC) on cancer cells. The modified T cells are then amplified in the laboratory and infused back into the patient. TCR-T cells can recognize both surface and intracellular protein as long as they are presented by MHCS, and have a larger repertoire of antigens they can target. These T cells also require less epitope density and are more efficient than CAR-T cells[8].

Despite the promising results of CAR-T cell and TCR-T cell therapy, there are still several challenges that need to be addressed. One challenge is in identifying tumor-specific antigens that are not expressed on healthy tissues, in order to avoid off-target toxicity. Another challenge is that some tumor antigens have Immune Checkpoint Receptors on their cell surfaces, which attack T cells and lead to early exhaustion of these cells. To overcome this, T cells can be treated with Immune Checkpoint Inhibitors, which inactive the IC Receptors and lead to a longer lasting immune response. Other challenges include the potential for toxic side effects, such as cytokine release syndrome and neurotoxicity, which can be life-threatening, as well as the accessibility of this treatment, as isolating T cells from the patient makes this therapy non-generalisable and hard to implement on a large scale. Despite these challenges, there has been progress in developing TCR T cell therapies for cancer. For example, a TCR T cell therapy targeting the NY-ESO-1 antigen has shown promising results in clinical trials for several types of solid tumors, including synovial sarcoma and melanoma. Among 107 patients treated in 5 trials, there was an average response rate of 47%[8]. There is a lot of research currently focused on addressing these challenges and improving the efficacy and safety of adoptive cell therapy for all types of cancer.

ML and DL in Cancer TIssue Biology

Machine learning (ML) is a type of Artificial Intelligence in which systems learn things from previous experience and use this experience to come to a conclusion about the existing data. It

can accelerate discovery in cancer research by enabling the analysis of large amounts of data and identifying patterns that may be difficult for human experts to detect[9].

The major advantage of ML is its ability to handle huge large datasets. For example, ML algorithms can be trained to identify patterns in gene expression data, which can help to identify genes that are upregulated or downregulated in cancer cells.

ML can also be used to analyze histological images, identifying features that may be difficult for pathologists to detect, such as subtle changes in cell shape or size. ML can help automate a lot of a pathologist's job, and reduce the error rate and time needed to analyze such images. They can also identify novel structures, such as foreign bodies and rare tumors, even if they are not trained for it.

Another advantage of ML is its ability to learn from new data. As more data becomes available, ML algorithms can be trained on this new data, improving their accuracy and ability to identify

patterns. ML can also be used to predict patient outcomes, based on a variety of factors such as genetic mutations, tumor size, and treatment history.

These predictions can help to guide treatment decisions and improve patient outcomes. However, ML does have some limitations, such as lack of sufficient training data, inconsistencies in this data being provided due to human error and limited computing power and memory[9].

Deep Learning is a subset of ML, which tries to train machines to think like humans, through the use of artificial neural networks. It is a more accurate and easy to use approach than ML, and has increasingly been used in the field of histopathology to accurately diagnose and come up with treatment plans. It has several advantages of ML, such as its ability to work with unstructured data, and generate high quality features without much human intervention. It has a reduced training time and very less computation cost, as well as an enhanced self learning ability due to the multiple layers present in learning networks[10].

Conclusion

The study of tissue features in cancer cells is a crucial area of research in cancer biology that can provide insights into the mechanisms driving cancer and can help identify new targets for therapy. Histology, particularly Hematoxylin and Eosin (H&E) staining and immunohistochemistry (IHC), are two important techniques used in cancer pathology to analyze cellular and tissue morphology, detect specific proteins or antigens, and identify prognostic markers. Immunotherapy is one of the upcoming methods of cancer treatment, and many advances have been made in this field to attempt to integrate it into the mainstream of cancer treatment. Machine learning (ML) and deep learning (DL) are also rapidly evolving areas of

cancer research that offer promising opportunities for improving cancer diagnosis and prognosis. By integrating these different approaches and techniques, researchers can gain a more comprehensive understanding of cancer biology and develop more effective treatments for cancer.

References:

1. Bancroft, J. D., & Gamble, M. (2008). Theory and Practice of Histological Techniques (6th ed.). Churchill Livingstone.
2. Kumar R, Srivastava R, Srivastava S. Detection and Classification of Cancer from Microscopic Biopsy Images Using Clinically Significant and Biologically Interpretable Features. J Med Eng. 2015;2015:457906. doi: 10.1155/2015/457906. Epub 2015 Aug 23. PMID: 27006938; PMCID: PMC4782618.
3. Sara Reis, Patrycja Gazinska, John H. Hipwell, Thomy Mertzanidou, Kalnisha Naidoo, Sarah Pinder, and David J. Hawkes "Classification of breast cancer stroma as a tool for prognosis", Proc. SPIE 9791, Medical Imaging 2016: Digital Pathology, 979105 (23 March 2016); https://doi.org/10.1117/12.2216520
4. Duraiyan J, Govindarajan R, Kaliyappan K, Palanisamy M. Applications of immunohistochemistry. J Pharm Bioallied Sci. 2012 Aug;4(Suppl 2):S307-9. doi: 10.4103/0975-7406.100281. PMID: 23066277; PMCID: PMC3467869.
5. Morrison, L.E., Lefever, M.R., Lewis, H.N. et al. Conventional histological and cytological staining with simultaneous immunohistochemistry enabled by invisible chromogens. Lab Invest 102, 545–553 (2022). https://doi.org/10.1038/s41374-021-00714-2
6. Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond). 2020 Apr;40(4):135-153. doi: 10.1002/cac2.12023. Epub 2020 Apr 17. PMID: 32301585; PMCID: PMC7170662.
7. Car T cells: Engineering immune cells to treat cancer. National Cancer Institute. (2022). https://www.cancer.gov/about-cancer/treatment/research/car-t-cells

8. Estelle Baulu et al. ,TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.Sci. Adv.9,eadf3700(2023).DOI:10.1126/sciadv.adf3700
9. Girnyak, M. (2021, December 2). Machine learning in digital pathology image analysis. PostIndustria. https://postindustria.com/machine-learning-in-digital-pathology-image-analysis-healthcare/
10. Ahmed AA, Abouzid M, Kaczmarek E. Deep Learning Approaches in Histopathology. Cancers (Basel). 2022 Oct 26;14(21):5264. doi: 10.3390/cancers14215264. PMID: 36358683; PMCID: PMC9654172.